Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2110
Nomenclature: myosin light chain kinase 3
Abbreviated Name: caMLCK
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 819 | 16q11.2 | MYLK3 | myosin light chain kinase 3 | |
Mouse | - | 795 | 8 C3 | Mylk3 | myosin light chain kinase 3 | |
Rat | - | 786 | 19q11 | Mylk3 | myosin light chain kinase 3 |
Previous and Unofficial Names |
MLC kinase | cardiac-MLCK | cardiac-MyBP-C-associated Ca/CaM kinase |
Database Links | |
Alphafold | Q32MK0 (Hs), Q3UIZ8 (Mm), E9PT87 (Rn) |
BRENDA | 2.7.11.18 |
ChEMBL Target | CHEMBL4627 (Hs) |
Ensembl Gene | ENSG00000140795 (Hs), ENSMUSG00000031698 (Mm), ENSRNOG00000017546 (Rn) |
Entrez Gene | 91807 (Hs), 213435 (Mm), 291926 (Rn) |
Human Protein Atlas | ENSG00000140795 (Hs) |
KEGG Enzyme | 2.7.11.18 |
KEGG Gene | hsa:91807 (Hs), mmu:213435 (Mm), rno:291926 (Rn) |
OMIM | 612147 (Hs) |
Pharos | Q32MK0 (Hs) |
RefSeq Nucleotide | NM_182493 (Hs), NM_175441 (Mm), NM_001110810 (Rn) |
RefSeq Protein | NP_872299 (Hs), NP_780650 (Mm), NP_001104280 (Rn) |
UniProtKB | Q32MK0 (Hs), Q3UIZ8 (Mm), E9PT87 (Rn) |
Wikipedia | MYLK3 (Hs) |
Enzyme Reaction | ||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: MLCK | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
Immuno Process Associations | ||
|
||
|
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
Myosin Light Chain Kinase (MLCK) family: myosin light chain kinase 3. Last modified on 18/08/2014. Accessed on 16/09/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2110.